Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:ATCCode |
none
|
| gptkbp:CASNumber |
1227477-70-0
|
| gptkbp:clinicalTrialPhase |
Phase II
|
| gptkbp:developedBy |
gptkb:Sanofi
gptkb:Exelixis |
| gptkbp:hasInChIKey |
gptkb:QJQJQJQJQJQJQJ-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
C23H24N4O3S
|
| gptkbp:hasSMILES |
C1COCCN1C2=NC(=NC(=N2)N3CCOCC3)C4=NC(=C(C=C4)N)C(F)(F)F
|
| gptkbp:hasUNII |
6Q1K1V0A6F
|
| https://www.w3.org/2000/01/rdf-schema#label |
voxtalisib
|
| gptkbp:indication |
gptkb:cancer
leukemia solid tumors glioma |
| gptkbp:IUPACName |
5-(2,6-dimorpholin-4-yl-pyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine
|
| gptkbp:mechanismOfAction |
PI3K/mTOR inhibitor
|
| gptkbp:molecularWeight |
436.5 g/mol
|
| gptkbp:PubChem_CID |
25154815
CHEMBL1800362 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
investigational drug
|
| gptkbp:synonym |
gptkb:SAR245409
XL765 |
| gptkbp:target |
gptkb:PI3K
gptkb:mTOR |
| gptkbp:bfsParent |
gptkb:XL518
|
| gptkbp:bfsLayer |
8
|